We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.14B
1-Year Est. Return 249.53%
This Fund
S&P 500
This Quarter Est. Return
+26.51%
1 Year Est. Return
+249.53%
3 Year Est. Return
+690.11%
5 Year Est. Return
+1,011.36%
10 Year Est. Return
+22,702.25%
AUM
$2.37B
AUM Growth
-$51.4M
Cap. Flow
-$112M
Cap. Flow %
-4.71%
Top 10 Hldgs %
45.23%
Holding
88
New
8
Increased
6
Reduced
18
Closed
10

Top Buys

Rank Stock Value
1
AXSM icon
Axsome Therapeutics
AXSM
+$105M
2
ZYME icon
Zymeworks
ZYME
+$41.2M
3
IMVT icon
Immunovant
IMVT
+$32.2M
4
PNT
POINT Biopharma Global Inc. Common Stock
PNT
+$26.6M
5
NAMS icon
NewAmsterdam Pharma
NAMS
+$15.1M

Top Sells

Rank Stock Value
1
RLMD icon
Relmada Therapeutics
RLMD
+$76.9M
2
IONS icon
Ionis Pharmaceuticals
IONS
+$73.7M
3
CINC
CinCor Pharma, Inc. Common Stock
CINC
+$43.1M
4
NUVL
Nuvalent
NUVL
+$32.4M
5
EQRX
EQRx, Inc. Common Stock
EQRX
+$29.7M

Sector Composition

Rank Sector Weight
1 Healthcare 99.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GBIO
76
DELISTED
Generation Bio
GBIO
$404K 0.02%
10,290
-25,892
-72% -$1.36M
RZLT icon
77
Rezolute
RZLT
$449M
$395K 0.02%
190,815
– –
NEUP
78
Neuphoria Therapeutics
NEUP
$21.5M
$373K 0.02%
6,748
– –
ETNB
79
DELISTED
89bio
ETNB
– –
-3,143,682
Closed -$18.2M
LITS
80
Lite Strategy Inc
LITS
$32.8M
– –
-176,603
Closed -$1.36M
NUVL
81
DELISTED
Nuvalent
NUVL
– –
-1,666,282
Closed -$32.4M
RLMD icon
82
Relmada Therapeutics
RLMD
$526M
– –
-2,078,220
Closed -$76.9M
SPRO icon
83
Spero Therapeutics
SPRO
$68.9M
– –
-1,929,376
Closed -$3.86M
PHXM
84
DELISTED
PHAXIAM Therapeutics S.A.. American Depositary Shares
PHXM
– –
-131,466
Closed -$690K
EQRX
85
DELISTED
EQRx, Inc. Common Stock
EQRX
– –
-6,008,187
Closed -$29.7M
CINC
86
DELISTED
CinCor Pharma, Inc. Common Stock
CINC
– –
-1,312,443
Closed -$43.1M
CFRX
87
DELISTED
ContraFect Corporation
CFRX
– –
-5,904
Closed -$79K
FWP
88
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
– –
-513,791
Closed -$1.52M
1 2 3
4

Similar funds

GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
BP
BNP Paribas Paris, France $3.15B AUM 22.54% 1-Year Est. Return
LFG
Larson Financial Group St Louis, Missouri $3.13B AUM 22.88% 1-Year Est. Return
DIG
DeepCurrents Investment Group New York $3.12B AUM 12.93% 1-Year Est. Return
CCI
Cevian Capital II St. Helier, Jersey $3.12B AUM 25.62% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
BFA
Bragg Financial Advisors Charlotte, North Carolina $3.16B AUM 26% 1-Year Est. Return

BVF Inc's Q4 2022 Portfolio in Review

As of Q4 2022, BVF Inc held 88 positions worth $2.37B, down 2.1% from $2.42B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

BVF Inc withdrew a net $112M in Q4 2022, closing 10 positions and reducing 18 holdings. Its most notable exit was Relmada Therapeutics, an estimated $76.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier.

Against the trend, BVF Inc opened a new position in Axsome Therapeutics worth $135M.

  • BVF Inc's largest Q4 2022 buy was Axsome Therapeutics: 1,755,000 shares worth $135M.
  • BVF Inc added most to POINT Biopharma Global Inc. Common Stock in Q4 2022, an estimated $26.6M increase.
  • BVF Inc's biggest Q4 2022 reduction was Ionis Pharmaceuticals, cutting an estimated $73.7M.
  • BVF Inc fully exited Relmada Therapeutics in Q4 2022, selling an estimated $76.9M.
  • BVF Inc's ten largest holdings make up 45% of its $2.37B portfolio in Q4 2022.
  • BVF Inc opened 8 new positions and closed 10 in Q4 2022.
  • BVF Inc's portfolio value fell 2.1% quarter-over-quarter to $2.37B.

Based on BVF Inc's 13F filing for Q4 2022, filed 14 Feb 2023.